



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/682,545	10/08/2003	Ward M. Peterson	03678.0073.DVUS04	9737

27194 7590 10/20/2005
HOWREY LLP
C/O IP DOCKETING DEPARTMENT
2941 FAIRVIEW PARK DRIVE, SUITE 200
FALLS CHURCH, VA 22042-2924

EXAMINER

KHARE, DEVESH

ART UNIT

PAPER NUMBER

1623

DATE MAILED: 10/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/682,545	Applicant(s) PETERSON ET AL.	
	Examiner Devesh Khare	Art Unit 1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-24 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>11/17/04; 7/16/04; 8/16/05</u> | 6) <input type="checkbox"/> Other: ____. |

Claims 1-24 are currently pending in this application.

An action on the merits of claims 1-24 is contained herein below.

Objection

Claim 20 is objected to because of the following informalities:

In claim 20, the abbreviations for the "mononucleoside triphosphate" should be preceded in their first occurrence by the specific identity of the entities said abbreviations are intended to represent in the claims. Thereafter, the use of the abbreviation in the claims will be favorably considered and explicitly understood.

Appropriate correction is required.

35 U.S.C. 112, first paragraph rejection

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-19 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while enabling the effects of only one synthetic P2Y₂ agonist UP₄dC on cloned human P2Y₂ receptors (specification: Examples 2-6), does not reasonably provide enablement for a method of treating edematous disorders in a subject in need thereof of claim 1. The selection of compounds having structural formula I of claim 1 wherein X is oxygen, methylene, halomethylene, or imido; Y or Y' = H, OH or N₃ and B or

Art Unit: 1623

B' are each a purine or a pyrimidine residue is too broad as the compound disclosed in Examples 2-6. In the absence of which of the compounds of claim 1 and in the absence of data disclosing the effectiveness of the compounds of claim 1 **for treating edematous retinal disorders in a subject**, the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

The factors regarding undue experimentation have been summarized in *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Circ. 1988) as follows:

- (1) The nature of the invention;
- (2) The state of the prior art;
- (3) The predictability or lack thereof in the art;
- (4) The amount of direction or guidance present;
- (5) The presence or absence of working examples;
- (6) The breadth of the claims;
- (7) The quantity of experimentation needed; and
- (8) The relative skill of those in the art.

THE NATURE OF THE INVENTION

The nature of the invention in claims 1-19 is a method of treating edematous retinal disorders in a subject in need thereof comprising administering to a subject a pharmaceutical composition comprising a dinucleoside polyphosphate compound of Formula I of claim 1.

THE STATE OF THE PRIOR ART

Art Unit: 1623

The instant claims are drawn to a method of treating edematous retinal disorders in a subject in need thereof comprising administering to a subject a pharmaceutical composition comprising a dinucleoside polyphosphate compound of Formula I of claim

1. The following references are cited to show the state of the prior art:

De Flora et al., U.S. Patent 6,040,297.

Maminishkis et al. IOVS, Nov. 2002, vol.43, no.11, pages 3555-3566.

(the prior art references are provided by the applicant in IDS dated 7/16/04 and 7/30/2003).

THE PREDICTABILITY OR LACK THEREOF IN THE ART

There would be little predictability in the art of which modifications may be made to a compound of claim 1 wherein X is oxygen, methylene, halomethylene, or imido; Y or Y' = H, OH or N₃ and B or B' are each a purine or a pyrimidine residue, which would retain its capability to treat edematous retinal disorders in a subject. The nature of the pharmaceutical arts is that it involves screening in vitro and in vivo to determine which compounds exhibit the desired pharmacological activities. There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face. In the absence of which Markush groups of the compounds depicted in claim 1 are being effective for the said treatment, there is no umbrella coverage springing forth from the claimed compounds for the said method.

THE AMOUNT OF DIRECTION OR GUIDANCE PRESENT

Art Unit: 1623

The structural formula of claim 1 may encompass a great number of compounds having various Markush groups, however, without some guidance as to what specific changes may be made to the instant compound effective for the said treatment, there would be little predictability in making and/or using such compounds. For example, there is no guidance as to which Markush groups may be selected to the specific compound that would retain its capability to treat edematous retinal disorders in a subject. One skilled in the art would not expect any modifications of the instant compound, which is effective for the said method.

THE PRESENCE OR ABSENCE OF WORKING EXAMPLES

The working Examples 2-6 disclose the effects of the effects of only one synthetic P2Y₂ agonist UP₄dC on cloned human P2Y₂ receptors.

BREATH OF THE CLAIMS

The breadth of the claims is that a method for inhibiting the growth of tumor cells in an individual by administering to the individual a pharmacologically effective dose of a compound having a general structural formula of claim 1.

THE QUANTITY OF EXPERIMENTATION NEEDED

The quantity of experimentation needed is undue experimentation. One skill in the art would need to determine what listed compounds from a broad selection depicted in claim 1 would be effective to use in a method of treating edematous retinal disorders in a subject in need thereof.

THE LEVEL OF SKILL IN THE ART

The level of skill in the art is high. However, due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity by in vitro and in vivo screening to determine which compounds exhibit the desired pharmacological activity **in a subject**. Thus the specification fails to provide sufficient support of the broad use of the compound having a structural formula of claim 1 because no specific compound is provided. As a result necessitating one of skill to perform an exhaustive search for which compound can be prepared in order to practice the claimed invention.

Genentech Inc. v Novo Nordisk A/S (CA FC) 42 USPQ 2d 1001, states that " a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and "[p] atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable."

Therefore, in view of the Wands factors discussed above, to practice the claimed invention herein, a person of skill in the art would have to engage in undue experimentation to test which compound out of a broad list of Markush groups of claim 1 is effective in the method encompassed in the instant claims, with no assurance of success.

Provisional "Non-Statutory" Double Patenting Rejection

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686

Art Unit: 1623

F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-24 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-18 of U.S. Patent No.6, 696,425 ('425); claims 1-15 of U.S. Patent 6,673,779 ('779); claims 1-34 of U.S. Patent 6,596,725 ('725); claims 11-20 of U.S. Patent 6,555,675 ('675); and claims 4-9 of U.S. Patent 6,348,589 ('589). Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims in each of the application and the '425; '779; '725; '675; and '589 patents are directed to substantially same subject matter, i.e., in the instant claims the invention is claimed in terms of the specific use of a pharmaceutical composition comprising the compounds of general structure of dinucleoside polyphosphate as defined in claim 1 or mononucleoside triphosphate of claim 20 to a subject in need thereof for treating edematous retinal disorders, while in the '425; '779; '725; '675; and '589 patents it is claimed in terms of a method for treating dry eye in a mammal ('589); a disease associated with a disorder of mucous hydration, secretion and clearance in a mammal ('675); edematous retinal disorders, retinal detachment, or retinal edema in a subject ('725); ciliary dyskinesia in a subject ('779);

Art Unit: 1623

and a method of stimulating tear secretion and mucin production in eyes ('425) by administering to said subject or mammal a pharmaceutical composition comprising the compounds of general structure of dinucleoside polyphosphate or mononucleoside triphosphate. The structures of structure of dinucleoside polyphosphate or mononucleoside triphosphate may well be varied in terms of its inherent activity, in this case to accomplish a method for treating edematous retinal disorders in a subject.

The examiner notes the instant claims and the '425; '779; '725; '675; and '589 patents claims do indeed substantially overlap and this obviousness-type double patenting rejection is necessary to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees.

Therefore the claims are co-extensive.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Any inquiry concerning this communication or earlier communications from the


Examiner should be directed to Devesh Khare whose telephone number is (571) 272-0653. The examiner can normally be reached on Monday to Friday from 8:00 to 4:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson, Supervisory Patent Examiner, Art Unit 1623 can be

Art Unit: 1623

reached at (571)272-0661. The official fax phone numbers for the organization where this application or proceeding is assigned is (703) 308-4556 or 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Devesh Khare, Ph.D.,JD.
Art Unit 1623
October 14, 2005



JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600